Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Biolinerx Ltd ADR (BLRX)

Biolinerx Ltd ADR (BLRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 47,164
  • Shares Outstanding, K 79,939
  • Annual Sales, $ 4,800 K
  • Annual Income, $ -60,610 K
  • 60-Month Beta 1.54
  • Price/Sales 9.83
  • Price/Cash Flow N/A
  • Price/Book 3.61
Trade BLRX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.76
  • Most Recent Earnings $-0.01 on 05/28/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 67.59% ( -149.10%)
  • Historical Volatility 85.89%
  • IV Percentile 21%
  • IV Rank 7.43%
  • IV High 767.80% on 07/27/23
  • IV Low 11.43% on 02/21/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 20
  • Volume Avg (30-Day) 81
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 4,984
  • Open Int (30-Day) 4,557

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.08
  • Number of Estimates 2
  • High Estimate -0.01
  • Low Estimate -0.14
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +73.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5760 +2.43%
on 06/21/24
0.8500 -30.59%
on 05/30/24
-0.0329 (-5.28%)
since 05/21/24
3-Month
0.5528 +6.73%
on 04/26/24
1.4000 -57.86%
on 03/22/24
-0.6100 (-50.83%)
since 03/21/24
52-Week
0.5528 +6.73%
on 04/26/24
2.5300 -76.68%
on 09/05/23
-1.0900 (-64.88%)
since 06/21/23

Most Recent Stories

More News
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth

EQNX::TICKER_START (ONASDAQ:ONCY),(TSX:ONC),(NASDAQ:BLRX),(NASDAQ:IMRX),(NASDAQ:CADL) EQNX::TICKER_END

ONCY : 1.0100 (+1.45%)
ONC.TO : 1.37 (+0.74%)
BLRX : 0.5900 (unch)
IMRX : 1.4300 (+1.42%)
CADL : 6.04 (+1.00%)
BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment

- License agreement includes $15 million upfront, up to $50 million in potential development and regulatory milestones; up to ~$200 million in potential...

BLRX : 0.5900 (unch)
BioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic Cancer

/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...

BLRX : 0.5900 (unch)
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

- On Track for September 9, 2023 PDUFA Target Action Date on NDA for Motixafortide in Stem Cell Mobilization (SCM) for Autologous Transplantation in Multiple...

BLRX : 0.5900 (unch)
BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investigational Candidate Motixafortide

/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial stage biopharmaceutical company pursuing life-changing therapies for certain...

BLRX : 0.5900 (unch)
BioLineRx to Report First Quarter 2023 Results on May 24, 2023

/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, announced today that it will...

BLRX : 0.5900 (unch)
BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in Stem Cell Mobilization for Autologous Transplantation in Multiple Myeloma

- GENESIS trial achieved statistical significance (p

BLRX : 0.5900 (unch)
BioLineRx to Report 2022 Annual Financial Results on March 22, 2023

/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, announced today that it will...

BLRX : 0.5900 (unch)
BLRX FINAL DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BioLineRx Ltd. Investors With Losses in Excess of $100K to Secure Counsel Before Important March 6 Deadline in Securities Class Action Filed by the Firm – BLRX

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioLineRx Ltd. (NASDAQ: BLRX) between February 23, 2021 and September 19, 2022, both dates inclusive (the...

BLRX : 0.5900 (unch)
BLRX MONDAY DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages BioLineRx Ltd. Investors with Losses to Secure Counsel Before Important March 6 Deadline in Securities Class Action Filed by the Firm - BLRX

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioLineRx Ltd. (NASDAQ: BLRX) between February...

BLRX : 0.5900 (unch)

Business Summary

Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company's portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040,...

See More

Key Turning Points

3rd Resistance Point 0.6337
2nd Resistance Point 0.6193
1st Resistance Point 0.6047
Last Price 0.5900
1st Support Level 0.5757
2nd Support Level 0.5613
3rd Support Level 0.5467

See More

52-Week High 2.5300
Fibonacci 61.8% 1.7747
Fibonacci 50% 1.5414
Fibonacci 38.2% 1.3081
Last Price 0.5900
52-Week Low 0.5528

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar